Isofol Medical Revenue vs. Cash Per Share
| ISOFOL Stock | SEK 2.33 0.09 4.02% |
For Isofol Medical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Isofol Medical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Isofol Medical AB utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Isofol Medical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Isofol Medical AB over time as well as its relative position and ranking within its peers.
Isofol |
Isofol Medical AB Cash Per Share vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Isofol Medical's current stock value. Our valuation model uses many indicators to compare Isofol Medical value to that of its competitors to determine the firm's financial worth. Isofol Medical AB is considered the number one company in revenue category among its peers. It also is currently regarded as number one stock in cash per share category among its peers . The ratio of Revenue to Cash Per Share for Isofol Medical AB is about 24,093,548 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Isofol Medical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Isofol Medical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Isofol Revenue vs. Competition
Isofol Medical AB is considered the number one company in revenue category among its peers. Market size based on revenue of Biotechnology industry is currently estimated at about 308.17 Million. Isofol Medical holds roughly 22.41 Million in revenue claiming about 7% of stocks in Biotechnology industry.
Isofol Cash Per Share vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Isofol Medical |
| = | 22.41 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Isofol Medical |
| = | 0.93 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Isofol Cash Per Share Comparison
Isofol Medical is currently under evaluation in cash per share category among its peers.
Isofol Medical Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Isofol Medical, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Isofol Medical will eventually generate negative long term returns. The profitability progress is the general direction of Isofol Medical's change in net profit over the period of time. It can combine multiple indicators of Isofol Medical, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Isofol Medical AB , a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden. Isofol Medical operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 12 people.
Isofol Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Isofol Medical. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Isofol Medical position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Isofol Medical's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Isofol Medical without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Price Ceiling Movement Now
Price Ceiling MovementCalculate and plot Price Ceiling Movement for different equity instruments |
| All Next | Launch Module |
Use Investing Themes to Complement your Isofol Medical position
In addition to having Isofol Medical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Marketing Thematic Idea Now
Marketing
Companies providing marketing and public relation (PR) services as well as news and media distribution. The Marketing theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Marketing Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Isofol Stock
To fully project Isofol Medical's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Isofol Medical AB at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Isofol Medical's income statement, its balance sheet, and the statement of cash flows.